logo-loader
NASDAQ:CNTX

Context Therapeutics

Receive alerts
Market:
NASDAQ
Price
1.47 USD
Day Change
5.76%
Market Cap:
$23.47 m
52 weeks high
1.68
52 weeks low
0.47

In brief

Context Therapeutics Inc. (Nasdaq: CNTX) is a clinical-stage biopharmaceutical company committed to advancing medicines for solid tumors, with a primary focus on female cancers. The Company’s pipeline includes small molecule and bispecific antibody drug candidates that target cancer signaling pathways. Context is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6 positive tumors, currently in preclinical development. Additionally, the company is advancing onapristone extended release (ONA-XR), a novel, first-in-class, potent, and selective progesterone receptor antagonist, currently in three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian, and endometrial cancers. Context is headquartered in Philadelphia.

Snapshot

  • Context Therapeutics prepares for CTIM-76 filing, ends 3Q with enough cash to last through late 2024
  • Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update

Insight Widest with the analysis, Proactive gives perspectives that others don't.

Context Therapeutics prepares for a busy 2022 as it advances women’s oncology treatments 

The clinical-stage biopharmaceutical company focused on bettering the lives of women living with cancer, is developing advanced small molecule and immunotherapy treatments to transform care for...

on 02/23/2022